Case Study: Psychopharmacology von Melissa Kalensky, FNP-BC, PMHNP-BC, CNE

video locked

Über den Vortrag

Der Vortrag „Case Study: Psychopharmacology“ von Melissa Kalensky, FNP-BC, PMHNP-BC, CNE ist Bestandteil des Kurses „Psychopharmacology Foundations: From Pharmacokinetics to Clinical Practice“.


Quiz zum Vortrag

  1. All IV drugs are 100% bioavailable, making it the only formulation that achieves complete bioavailability.
  2. IV drugs have 90-95% bioavailability due to immediate metabolism in the bloodstream.
  3. IV drugs have variable bioavailability depending on the specific medication administered.
  4. IV drugs achieve 100% bioavailability only when given in high concentrations.
  5. IV drugs have the same bioavailability as intramuscular formulations.
  1. ...determining the area under the curve on a plasma concentration versus time graph.
  2. ...measuring peak plasma drug concentration at maximum absorption.
  3. ...calculating the time to reach maximum drug concentration in tissues.
  4. ...determining the total amount of drug excreted in urine over 24 hours.
  5. ...measuring the rate of drug clearance from systemic circulation.
  1. The liver, which breaks down drugs to make them easier to excrete
  2. The kidneys, which filter drugs directly from the bloodstream
  3. The lungs, which process lipophilic drugs through respiratory pathways
  4. The intestines, which metabolize drugs before systemic absorption
  5. The heart, which pumps drugs through metabolic circulation pathways
  1. About every decade of life after age 30, with 80-year-olds having approximately half the renal function of 30-year-olds
  2. About every five years after age 40, with 70-year-olds having one-third the renal function of 40-year-olds
  3. About every 15 years after age 25, with 85-year-olds having 25% of the renal function of 25-year-olds
  4. About every decade after age 40, with 90-year-olds having 10% of the renal function of 40-year-olds
  5. About every eight years after age 35, with 75-year-olds having 40% of the renal function of 35-year-olds
  1. Individual patient characteristics including blood perfusion, tissue binding (e.g., adipose for lipophilic drugs), regional pH, and cell membrane permeability
  2. Differences in drug formulation and manufacturing processes across pharmaceutical companies
  3. Variations in environmental temperature and humidity affecting drug stability
  4. Individual differences in stomach acidity and gastrointestinal motility patterns
  5. Genetic variations in drug absorption rates through intestinal membranes
  1. It is primarily processed through the CYP2C19 pathway, which does not overlap with methadone's metabolism.
  2. It has the shortest half-life among antidepressants, reducing accumulation risks in older adults.
  3. It does not require hepatic metabolism, making it safe for patients with liver cirrhosis.
  4. It is exclusively excreted through the kidneys without any liver involvement.
  5. It has no interactions with cytochrome P450 enzymes used by other medications.

Dozent des Vortrages Case Study: Psychopharmacology

 Melissa Kalensky, FNP-BC, PMHNP-BC, CNE

Melissa Kalensky, FNP-BC, PMHNP-BC, CNE

Dr. Melissa Kalensky, FNP-BC, PMHNP-BC, CNE is dual-certified as a Family Nurse Practitioner and a Psychiatric Mental Health Nurse Practitioner.

She specializes in primary care, community health, and integrated behavioral healthcare. Her expertise spans trauma-informed care and psychiatry across all age groups, from children to adults.

At Lecturio, she teaches psychopharmacology to advanced practice providers, helping to bridge the gap between psychiatric and primary care practice.


Kundenrezensionen

(1)
5,0 von 5 Sternen
5 Sterne
5
4 Sterne
0
3 Sterne
0
2 Sterne
0
1  Stern
0